While I enjoy being in academia (although I would hardly consider myself a real scientist), I also greatly appreciated this article by Adam Ruben. (Also, were you my DM at Princeton Band?!)

Fascinating stuff - need both a promoter and an initiator to develop lung cancer - eg, EGFR mutation + pollution. Air Pollution and Lung Cancer: A Q ilcn.org/air-pollution-…

Always a pleasure speaking with Brendon Stiles and PeerView! Excited to hear OS data for ADAURA at #ASCO2023! #AATS2023 (Here I am secretly pretending I'm a thoracic surgeon)

Bravi! Absolutely right, & we're stressing NGS every day throughout our multi-stakeholder organization, exon20group.org ...so your excellent JTO & JTO CRR commentary building upon Santiago Viteri + Joshua Bauml, MD + Anna Minchom + LudaBazhenovaMD article, febs.onlinelibrary.wiley.com/doi/full/10.10… is

#ASCO23 ASCO KN671 - 1st IA: Periop ChemoIO + Adj IO Dual endpts EFS/OS N=797–>397 in P ✨~40% completed adj tx ✨1/3rd split across PDL1 levels ✨EFS HR=0.58, mEFS NR w P ✨OS HR=0.73 OncoAlert The ASCO Post

When discussing adjuvant osimertinib- can’t downplay chronic toxicity of long term targeted therapy. Dr. Ben Solomon credits Jill Feldman for highlighting this critical aspect of cancer care - with rousing applause from the #ASCO23 audience.

Yes!!! I see all this all the time in my practice. That being said, it was chilling to see the results of #ADAURA being presented by Roy Herbst!

Yes!! Superb Jonathan Riess, MD MS analysis of Keynote-789, zorifertinib, and sunvozertinib. Promising ORR and CNS activity for #sunvozertinib in #EGFR #Exon20 and it will be important to see sunvo continue to be studied in the treatment-naive setting. #ASCO23

Very excited about this one!

Can’t believe the air quality today. And then of course I can’t stop thinking about Charles Swanton’s paper on lung adenocarcinoma promotion by air pollution… nature.com/articles/s4158…

What an honor to play even a small part of this - thank you to all involved! It was fun hanging out with surgeons, digesting all the new information in this space.

To all of the Melanoma and/or Rare Tumor Experts in the Twitterverse - We are recruiting Herbert Irving Comprehensive Cancer Center in NYC. If you ❤️NY and are interested in joining our exceptional team DM me. cancer.columbia.edu

PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma Eric Lim. Practice changing results based on a clinically relevant design. #LCSM #WCLC23 IASLC OncoAlert

I am looking forward to presenting RAMOSE trial in EGFR mut lung cancer pts at #ESMO23 LBA71 MD Anderson Cancer Center EGFR Resisters @exon20

PAPILLON triplet = new 1L standard of care (NEJM!) Dr Girard read-out rocks Exon 20 Group! We saw the great outcomes in the trenches & are thrilled with the official 66% ORR + consistent PFS >12 mo. Death risk reduced by 30%. Tolerable👍 regimen, few discontinuations. #ESMO2023

I am thankful for patients like Oswald who make our job so gratifying! Who knew all those years ago we’d be on this path today.

Thanks Great Debates for having me! Turns out there were a lot of secret Swifties in the audience!